URINARY NEOPTERINE LEVELS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: ALTERATIONS AFTER TREATMENT WITH PAROXETINE AND COMPARISON WITH HEALTHY CONTROLSReportar como inadecuado




URINARY NEOPTERINE LEVELS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: ALTERATIONS AFTER TREATMENT WITH PAROXETINE AND COMPARISON WITH HEALTHY CONTROLS - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Psychiatria Danubina, Vol.27 No.1 March 2015. -

Background: A close relationship has been shown between mood disorders and pteridine levels. The aim of this study was to

examine alterations in the urine neopterine levels of patients with major depressive disorder MDD who responded to paroxetine

during the initial treatment and to compare their levels to those of healthy controls.

Subjects and methods: Sixteen patients with major depression and 19 healthy controls were enrolled in the study. In order to

assess depression severity levels, the Beck Depression Inventory, the Beck Anxiety Inventory, and the State-Trait Anxiety Inventory

were administered. Urinary neopterine values that were measured using high pressure liquid chromatography HPLC were

compared using non-parametric tests for the MDD patients before and after treatment. Urine neopterine levels in MDD patients

before and after treatment were compared to those of the healthy control group.

Results: Urinary neopterine levels were recorded as follows: For the MDD group before treatment the mean level was

187.92±54.79 μmol-creatinine. The same group under treatment at 4 to 8 weeks was at 188.53±4962 μmol-creatinine, and the

healthy control group showed 150.57±152.98 μmol-creatinine levels. There was no statistically significant difference in the urinary

neopterine levels among the MDD patients before and after treatment p=0.938. When urine neopterine levels in MDD patients

before and after treatment were compared to those of the healthy control group, levels in the MDD group were found to be

significantly higher p=0.004 and p=0.005, respectively.

Conclusions: Findings from the current study suggest that despite treatment response, depression is related to higher levels of

urine neopterine. Paroxetine treatment has no significant effect on urine levels of neopterine in MDD patients.

neopterine – depression – MDD - immune system - paroxetine



Autor: Ibrahim Taymur - ; Department of Psychiatry, Şevket Yilmaz Teaching and Research Hospital, Bursa, Turkey Kadir Özdel - orcid.or

Fuente: http://hrcak.srce.hr/



DESCARGAR PDF




Documentos relacionados